HEALTHCARE RESOURCE BURDEN IN KIDNEY TRANSPLANT RECIPIENTS WITH ACTIVE AND CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION: RESULTS FROM A REAL-WORLD SURVEY IN GERMANY AND THE USA
Author(s)
Aditi Gupta, PhD1, Katie Stenson, MSc2, Sarah Clayton, BSc3, Mollie Lowe, MSc3, Laura LeBrocq, BSc3, Samir Patel, PharmD, MPH2, Klemens Budde, MD4.
1Department of Internal Medicine, University of Kansas, KU Medical Center, Kansas City, KS, USA, 2Biogen, Cambridge, MA, USA, 3Adelphi Real World, Bollington, United Kingdom, 4Charité Universitätsmedizin Berlin, Berlin, Germany.
1Department of Internal Medicine, University of Kansas, KU Medical Center, Kansas City, KS, USA, 2Biogen, Cambridge, MA, USA, 3Adelphi Real World, Bollington, United Kingdom, 4Charité Universitätsmedizin Berlin, Berlin, Germany.
OBJECTIVES: Antibody-mediated rejection (AMR), a key driver of graft loss in kidney transplantation, requires complex, resource-intensive management. We described healthcare resource utilization (HCRU) in patients with AMR post kidney transplant.
METHODS: Data are from the Adelphi Real World AMR Disease Specific Programme™, a cross-sectional physician-reported survey with retrospective data collection from Feb-Apr 2026. Nephrologists in Germany and the USA reported on their patients with active/chronic active AMR. Descriptive analyses were conducted, with data presented as median (IQR).
RESULTS: Interim results from 164 patients with active/chronic active AMR are presented. Patient age was 55.0 (47.0-61.0) years; 57% were male. Time since transplant was 3.0 (2.0-5.0) years, and time since AMR diagnosis was 11.0 (8.0-15.0) months. At the time of survey, 99% of patients received maintenance immunosuppression (median of 3.0 [1.2-3.0] treatments), most commonly tacrolimus (75%), prednisone (66%), and mycophenolate mofetil (55%). Additionally, 54% of patients received treatment for side effects of AMR therapies or AMR-related symptoms; among these patients, 77% were prescribed ≥5 treatments, most commonly statins/antihypertensives (85%) and antimicrobials (78%). In the 12 months prior to survey, patients had 14.0 (7.2-22.8) healthcare professional consultations, including 8.0 (5.0-12.0) consultations with transplant nephrologists; 27% had consulted an infectious disease specialist as part of their care.AMR-related hospitalizations occurred in 36% of patients in the prior 12 months. For the most recent hospitalization, patients spent 4.0 (3.0-5.0) nights in hospital; 30% were admitted via the emergency room and 16% spent time in the ICU for 2.0 (1.0-2.2) nights.
CONCLUSIONS: Patients with active/chronic active AMR have substantial ongoing healthcare utilization, reflected in frequent specialist consultations, polypharmacy, and high hospitalization rates, including emergency admissions and ICU stays. These findings highlight the substantial HCRU burden of AMR and underscore the need for innovative management strategies to alleviate the strain on healthcare systems and treatment complexity.
METHODS: Data are from the Adelphi Real World AMR Disease Specific Programme™, a cross-sectional physician-reported survey with retrospective data collection from Feb-Apr 2026. Nephrologists in Germany and the USA reported on their patients with active/chronic active AMR. Descriptive analyses were conducted, with data presented as median (IQR).
RESULTS: Interim results from 164 patients with active/chronic active AMR are presented. Patient age was 55.0 (47.0-61.0) years; 57% were male. Time since transplant was 3.0 (2.0-5.0) years, and time since AMR diagnosis was 11.0 (8.0-15.0) months. At the time of survey, 99% of patients received maintenance immunosuppression (median of 3.0 [1.2-3.0] treatments), most commonly tacrolimus (75%), prednisone (66%), and mycophenolate mofetil (55%). Additionally, 54% of patients received treatment for side effects of AMR therapies or AMR-related symptoms; among these patients, 77% were prescribed ≥5 treatments, most commonly statins/antihypertensives (85%) and antimicrobials (78%). In the 12 months prior to survey, patients had 14.0 (7.2-22.8) healthcare professional consultations, including 8.0 (5.0-12.0) consultations with transplant nephrologists; 27% had consulted an infectious disease specialist as part of their care.AMR-related hospitalizations occurred in 36% of patients in the prior 12 months. For the most recent hospitalization, patients spent 4.0 (3.0-5.0) nights in hospital; 30% were admitted via the emergency room and 16% spent time in the ICU for 2.0 (1.0-2.2) nights.
CONCLUSIONS: Patients with active/chronic active AMR have substantial ongoing healthcare utilization, reflected in frequent specialist consultations, polypharmacy, and high hospitalization rates, including emergency admissions and ICU stays. These findings highlight the substantial HCRU burden of AMR and underscore the need for innovative management strategies to alleviate the strain on healthcare systems and treatment complexity.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD111
Topic
Real World Data & Information Systems
Disease
Urinary/Kidney Disorders